$LPCN 8-K SEC Filings

The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.1.

SALT LAKE CITY, October 7, 2026 -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine’s licensing partner Verity Pharmaceuticals ...

On September 16, 2026, the Company presented at H.C. Wainwright 28th Annual Global Investor Conference which was being held September 14 – 16, 2026, in New York City, NY. A copy of the presentation is furnished as Exhibit 99.1 to this re...

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

SALT LAKE CITY, September 10, 2026 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at ...